Specific immunohistochemical expression of Mmp-26 in prostatic adenocarcinoma.

Abstract

Matrix metalloproteinases (MMP) have been identified as biomarkers for several diseases, including cancer. The increase in the expression of these enzymes has been related to greater tumor aggressiveness. MMP-26 is expressed constitutively in the endometrium and some cancer cells of epithelial origin. However, there is a lack of studies on its expression on prostatic carcinoma. In this study, the evaluation of MMP-26 reactivity by immunohistochemistry (IHC) was carried out in 150 paraffinized samples representative of benign and malignant prostatic lesions. 70 of the 150 samples showed IHC immunopositivity, being more prevalent in carcinoma cases (44 out of 70 cases) with moderate and strong intensity. The expression and intensity of the MMP-26 reaction showed a significant association with total PSA values. As expected, serum PSA levels were higher in cases of carcinoma than in prostatic hyperplasia or atrophy. Studies have demonstrated the potential of MMP-26 as a tumor marker, and our results have shown that its immunoexpression was useful to differentiate a group of benign and malignant samples in prostate tumors. This characteristic can assist in the predictive assessment and, consequently, in the development of new strategies for the diagnosis, prognosis, and treatment of prostate cancer.